A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma

OBJECTIVES: Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted therapy, also was assessed in a single-arm trial (ERIVANCE). We e...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Skin Cancer
Main Authors: Odom, Dawn, Mladsi, Deirdre, Purser, Molly, Kaye, James A., Palaka, Eirini, Charter, Alina, Jensen, Jo Annah, Sellami, Dalila
Format: Artigo
Jezik:Inglês
Izdano: Hindawi 2017
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457749/
https://ncbi.nlm.nih.gov/pubmed/28607774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6121760
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki